I-Mab’s CEO is hoping its recent reorganization — splitting its US and China operations — will simplify its investment thesis by shifting the risk profile and focusing its resources, after the biotech struggled to win over investors.
ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.
As I-Mab Biopharma embarks on its next chapter as a fully US-based company, it’s parting ways with more executives from the old era.
I-Mab Reports Full Year 2023 Financial Results and Business Update
I-Mab, a global biotech company exclusively focused on bringing highly differentiated immunotherapies and biologics for cancer treatment to patients around the world, has announced that as part of its strategy to become a US-based biotech, its Chinese subsidiaries have entered into definitive agreements with I-Mab Biopharma (Hangzhou), an unconsolidated affiliate of the company, and a group of China-based investors to divest the company's assets and business operations in China.
I-Mab Biopharma’s plan to become a U.S.-focused biotech took a stride forward with the news that the company is divesting its China operations.